Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 12, 2011, Pages 2664-2674

  Scuderi, Caterina ^a,b   Esposito, Giuseppe ^a   Blasio, Angelo ^a   Valenza, Marta ^a   Arietti, Pierluca ^a   Steardo Jr , Luca ^c   Carnuccio, Rosa ^d   De Filippis, Daniele ^d   Petrosino, Stefania ^e   Iuvone, Teresa ^d   Di Marzo, Vincenzo ^e   Steardo, Luca ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e CNR   (Italy)

Author keywords

amyloid; Astrocyte; Neuroinflammation; Palmitoylethanolamide; PPAR

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PALMIDROL; PALMITIC ACID DERIVATIVE; PEPTIDE FRAGMENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL; ARTICLE; ASTROCYTE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; GENETICS; GLIOSIS; HUMAN; INFLAMMATION; METABOLISM; NEWBORN; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTROCYTES; BLOTTING, WESTERN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GLIOSIS; HUMANS; INFLAMMATION; PALMITIC ACIDS; PEPTIDE FRAGMENTS; PPAR ALPHA; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79953662512     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01267.x     Document Type: Article

References (51)

1. Craft JM, Watterson DM, Van Eldik LJ. Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia. 2006; 53: 484-90.
2. Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140: 918-34.
3. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron. 2002; 35: 419-32.
4. DeLegge MH, Smoke A. Neurodegeneration and inflammation. Nutr Clin Pract. 2008; 23: 35-41.
5. Skaper SD. The brain as a target for inflammatory processes and neuroprotective strategies. Ann NY Acad Sci. 2007; 1122: 23-34.
6. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging. 2001; 22: 903-8.
7. Zhang D, Hu X, Qian L, et al. Astrogliosis in CNS pathologies: is there a role for microglia Mol Neurobiol. 2010; 41: 232-41.
8. Eikelenboom P, Bate C, Van Gool WA, et al. Neuroinflammation in Alzheimer's disease and prion disease. Glia. 2002; 40: 232-9.
9. Maccioni RB, Rojo LE, Fernández JA, et al. The role of neuroimmunomodulation in Alzheimer's disease. Ann NY Acad Sci. 2009; 1153: 240-6.
10. Rogers J, Strohmeyer R, Koveleowski CJ, et al. Microglia and inflammatory mechanisms in the clearance of amyloid b peptide. Glia. 2002; 40: 260-9.
11. Rojo LE, Fernández JA, Maccioni AA, et al. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res. 2008; 39: 1-16.
12. Blanco A, Alvarez S, Fresno M, et al. Amyloid-β induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-κ B dependent manner. J Alzheimers Dis. 2010; 22.
13. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol. 2009; 86: 505-12.
14. Liao YF, Wang BJ, Cheng HT, et al. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem. 2004; 279: 49523-32.
15. Tachida Y, Nakagawa K, Saito T, et al. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. J Neurochem. 2008; 104: 1387-93.
16. Bélanger M, Magistretti PJ. The role of astroglia in neuroprotection. Dialogues Clin Neurosci. 2009; 11: 281-95.
17. Duncan RS, Chapman KD, Koulen P. The neuroprotective properties of palmitoylethanolamine against oxidative stress in a neuronal cell line. Mol Neurodegener. 2009; 4: 50.
18. LoVerme J, La Rana G, Russo R, et al. The search for the palmitoylethanolamide receptor. Life Sci. 2005; 77: 1685-98.
19. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players.AAPS J. 2006; 8: E298-306.
20. Calignano A, La Rana G, Giuffrida A, et al. Control of pain initiation by endogenous cannabinoids. Nature. 1998; 394: 277-81.
21. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 2001; 419: 191-8.
22. Franklin A, Parmentier-Batteur S, Walter L, et al. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci. 2003; 23: 7767-75.
23. Jaggar SI, Hasnie FS, Sellaturay S, et al. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 1998; 76: 189-99.
24. Lambert DM, Vandevoorde S, Diependaele G, et al. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia. 2001; 42: 321-7.
25. Mazzari S, Canella R, Petrelli L, et al. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 1996; 300: 227-36.
26. Sheerin AH, Zhang X, Saucier DM, et al. Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia. 2004; 45: 1184-8.
27. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA. 1996; 93: 3984-9.
28. Hansen HS, Diep TA. N-acylethanolamines, anandamide and food intake. Biochem Pharmacol. 2009; 78: 553-60.
29. Capasso R, Izzo AA, Fezza F, et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol. 2001; 134: 945-50.
30. De Petrocellis L, Bisogno T, Ligresti A, et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol. 2002; 16: 297-302.
31. Di Marzo V, Melck D, Orlando P, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. 2001; 358: 249-55.
32. Bouchard JF, LÈpicier P, Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci. 2003; 72: 1859-70.
33. LoVerme J, Russo R, La Rana G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther. 2006; 319: 1051-61.
34. Re G, Barbero R, Miolo A, et al. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J. 2007; 173: 21-30.
35. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci. 1997; 17: 1226-42.
36. Murillo-Rodriguez E, Désarnaud F, Prospéro-Garcìa O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci. 2006; 79: 30-7.
37. Vairano M, Dello Russo C, Pozzoli G, et al. Erythropoietin exerts anti-apoptotic effects on rat microglial cellsin vitro. Eur J Neurosci. 2002; 16: 584-92.
38. Di Rosa M, Radomski M, Carnuccio R, et al. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun. 1990; 172: 1246-52.
39. Petrosino S, Iuvone T, Di Marzo V. N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie. 2010; 92: 724-7.
40. Escartin C, Bonvento G. Targeted activation of astrocytes: a potential neuroprotective strategy. Mol Neurobiol. 2008; 38: 231-41.
41. Bodles AM, Barger SW. Secreted beta-amyloid precursor protein activates microgliaviaJNK and p38-MAPK. Neurobiol Aging. 2005; 26: 9-16.
42. Ho GJ, Drego R, Hakimian E, et al. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy. 2005; 4: 247-56.
43. Akama KT, Van Eldik LJ. B-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β- and tumor necrosis factor-α (TNF-α)-dependent, and involves a TNF-α receptor-associated factor- and NF-κB-inducing kinase-dependent signaling mechanism. J Biol Chem. 2000; 275: 7918-24.
44. Hensley RA, Floyd RA, Zheng NY, et al. p38 kinase is activated in the Alzheimer's disease brain. J. Neurochem. 1999; 72: 2053-8.
45. O'Neill LAJ, Kaltschmidt C. NF-κB: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997; 20: 252-8.
46. Walker DG, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J Neurosci Res. 2005; 81: 412-25.
47. Zhu X, Raina AK, Rottkamp CA, et al. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem. 2001; 76: 435-41.
48. Zhu X, Castellani RJ, Takeda A, et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev. 2001; 123: 39-46.
49. O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology. 2010; 215: 611-6.
50. Lambert DM, Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic Curr Med Chem. 1999; 6: 757-73.
51. Esposito G, Iuvone T, Savani C, et al. Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis:in vitroandin vivoevidence. J Pharmacol Exp Ther. 2007; 322: 1144-52.